imexon

{{Short description|Chemical compound}}

{{Drugbox

| Verifiedfields = changed

| Watchedfields = changed

| verifiedrevid = 449590785

| IUPAC_name = 4-imino-1,3-diazabicyclo[3.1.0]hexan-2-one

| image = Imexon.svg

| tradename =

| pregnancy_AU =

| pregnancy_US =

| pregnancy_category =

| legal_AU =

| legal_CA =

| legal_UK =

| legal_US =

| legal_status =

| routes_of_administration =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life =

| excretion =

| CAS_number_Ref = {{cascite|correct|??}}

| CAS_number = 59643-91-3

| ATC_prefix = none

| ATC_suffix =

| PubChem = 68791

| DrugBank_Ref = {{drugbankcite|correct|drugbank}}

| DrugBank =

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = 8F63U28T2V

| KEGG_Ref = {{keggcite|correct|kegg}}

| KEGG = D08932

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = 62031

| C=4 | H=5 | N=3 | O=1

| smiles = O=C1/N=C(/N)C2N1C2

| StdInChI_Ref = {{stdinchicite|changed|chemspider}}

| StdInChI = 1S/C4H5N3O/c5-3-2-1-7(2)4(8)6-3/h2H,1H2,(H2,5,6,8)

| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}

| StdInChIKey = BIXBBIPTYBJTRY-UHFFFAOYSA-N

}}

Imexon (INN, trade name Amplimexon) is a substance that is being studied in the treatment of some types of cancer, including pancreatic, lung, breast, prostate, melanoma, and multiple myeloma. It is a cyanoaziridine derivative.